Four Colorado Bioscience Companies Present at the Inaugural White Hat Life Science Investor Conference in Phoenix
Colorado BioScience Association (CBSA) congratulates the
four Colorado headquartered companies selected to present at the inaugural White Hat Life Science Investor Conference being
held September 17 and 18 at the Grand Hyatt in Phoenix, AZ. The announcement is made by April Giles, CBSA President and CEO,
who says, “We’re excited to be a partner in the 2014 White Hat Life Science Investor Conference and to help showcase
three of Colorado’s promising bioscience companies during the event.” The participating Colorado companies include
EndoShape, Fluonic, ValveXchange and ViroCyt.
conference, spearheaded by the Arizona BioIndustry Association (AZBio), is presented by the National Venture Capital Association
and leading life science associations of the Rocky Mountain Southwest Region, including the CBSA. This conference is showcasing
34 of the region’s top life science companies to interested investors including business development professionals from
large pharmaceutical, biotechnology, medical device and diagnostic companies.
“The Rocky Mountain and Southwest Regions have become increasingly recognized for their
growth in the bioscience and heath care innovations. The White Hat Life Science Investor Conference will act as another opportunity
to highlight the work being done in Colorado and the surrounding region while at the same time bringing new potential partners
and investors into our community,” Giles said. Colorado bioscience companies selected to present in the 2014 White Hat Investor Conference:
* EndoShape, Inc., Boulder – EndoShape’s
mission is to commercialize novel medical devices based on its proprietary polymer technology. EndoShape is focused on the
coil embolization and occlusion market. EndoShape is currently commercializing the Medusa™ Vascular Plug which is FDA
510(k) cleared for sale in the United States. Visit, http://www.endoshape.com.
* Fluonic, Inc., Boulder - Fluonic is a privately held medical device company dedicated to making infusion drug
delivery safer for patients through the development of a new generation of infusion devices and information systems, driven
by a breakthrough MEMS flow sensor technology. Fluonic infusion products improve patients’ safety and compliance while
improving medical staff productivity and reducing costs, which will set a new standard of care for the industry. Visit,http://fluonic.com.
* ValveXchange, Inc. – Greenwood Village –
ValveXchange (VXi) is dedicated to improving the lives of patients requiring heart valve replacements. VXi is developing a
two-piece bioprosthetic tissue valve system that resolves the long standing compromises between conventional mechanical and
tissue-based prosthetic valves. Unlike today’s transcatheter valves, the VXi technology is Without Compromise. The VXi
exchangeable valve system is being designed to offer leaflet exchange, as well as the original implant, without open-heart
surgery and without the safety and longevity compromises of transcatheter approaches. Visit: http://www.valvexchange.com.
* ViroCyt, LLC, Boulder - ViroCyt, LLC was created in late 2012 to focus on the commercialization of novel technologies
that enable rapid quantification of viruses, such as the Virus Counter® 3100. The Company’s mission is to provide
the tools that deliver meaningful improvements to critical biotechnology processes such as vaccine manufacturing, protein
expression, antiviral development and other settings where viruses play a significant role. Visit, http://www.virocyt.com.
Colorado Med Device Company dBMEDx Wins the Venture Showcase Competition at BioWest 2014
dBMEDx (Littleton)won the 2014 Venture Showcase competition at the BioWest Conference
and Expo yesterday at the Marriott City Center Denver, receiving the $7,500 cash prize. The announcement is made by April
Giles, Colorado BioScience Association (CBSA) President and CEO who says, “We are very proud to announce dBMEDx as the
winner of the Venture Showcase. The check presentation was an exciting end to the BioWest Conference. The award not only includes
the cash prize of $7,500 but also includes recognition and exposure for the company. ” This award is sponsored by Dorsey
and Whitney LLP and The Metro Denver Economic Development Corporation. BioWest, the Rocky Mountain Region's premier medical
device and biotechnology conference, is organized by the CBSA and held every other year.
dBMEDx is a Colorado-based medical device development company that is creating clinical decision and patient
monitoring devices using its patented, non-invasive scanning technology. These devices combine the power and safety of ultrasound
with sophisticated image processing electronics and software to provide simple, fully automated and completely noninvasive
diagnostic measurements. Fully automated means that very little training is required and the user does not need any
experience with ultrasound to use our devices. To enable this level of automation, dBMEDx has successfully created and patented
an extremely compact, wireless, 3D scan engine.
The scan engine, which can be held in the palm of the hand, includes a complete 3D ultrasound imaging
machine and automated image processor within a small, sealed tube. The system also includes an integrated Bluetooth
radio and rechargeable battery, which is inductively charged. The company is in the process of commercializing the first application
for this technology, the BBS Revolution™ device for automated bladder volume measurement, and has a range of pipeline
of products for other clinical applications as well. Visit: http://www.dbmedx.com. Video of winning Venture Showcase pitch by dBMEDx
CEO David Shine:
The Venture Showcase format allowed each company’s lead executive to make a 15-minute presentation
with an accompanying slide deck explaining their technology and business plan to a panel of judges in front of a live audience.
This year's judging panel included the following:
• Michael Weiner, Partner, Dorsey • Ned Scheetz, Managing Director, Aphelion Capital • Steve VanNurden,
President and CEO, Fitzsimons Redevelopment Authority
The three 2014 Venture Showcase finalists included:
The BioWest Conference was attended by more than 300 industry leaders, government representatives, executives,
researchers, investors and entrepreneurs. “We look forward to the continued growth of the bioscience industry and presenting
the conference in again 2016,” Giles concludes.